Bain Capital Life Sciences Discloses Position in CARA / Cara Therapeutics

Fintel reports that Bain Capital Life Sciences Opportunities III, LP has filed a 13G form with the SEC disclosing ownership of 2,696,030 shares of Cara Therapeutics Inc (CARA). This represents 5.0% of the company.Cara Therapeutics is a clinical-stage biopharmaceutical company foc

admin